Vibrio vulnificus Infection in a Hemodialysis Patient Receiving Intravenous Iron Therapy

Barton, James C.; Coghlan, Michael E.; Reymann, Michael T.; Ozbirn, Thomas W.; Acton, Ronald T.
September 2003
Clinical Infectious Diseases;9/1/2003, Vol. 37 Issue 5, pe63
Academic Journal
A 73-year-old man treated with long-term hemodialysis, erythropoietin, and intravenous iron sucrose infusions developed Vibrio vulnificus infection after eating raw oysters harvested from the Alabama coast. Five of the 31 persons with cases of V. vulnificus infection reported to the Alabama Department of Public Health (Montgomery) during 1996-2002 (including the patient described here) also had renal disease. Persons with renal disease, especially those treated with long-term hemodialysis and intravenous iron infusions, may have an increased risk of infection with V. vulnificus.


Related Articles

  • Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. López-Gómez, Juan M.; Portolés, José M.; Aljama, Pedro // Kidney International Supplement;Dec2008, Issue 111, pS75 

    The response to erythropoietin-stimulating agents (ESA) can vary among different patients and according to the different circumstances over time within a given individual. The aim of this study was to analyze the factors that can modify the response to epoetin in patients on hemodialysis (HD)...

  • Molecular biology of erythropoietin. Ratcliffe, Peter J. // Kidney International;Oct1993, Vol. 44 Issue 4, p887 

    A 42-year-old man presented with hypertension and proteinuria 22 years ago and was found to have adult polycystic kidney disease. Within 8 years he was approaching end-stage renal failure (creatinine clearance, 10 ml/min). The hemoglobin (Hb) was 10.0 g/dl. Hemodialysis was initiated 13 years...

  • Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial. McMahon, Lawrence P.; Kent, Annette B.; Kerr, Peter G.; Healy, Helen; Irish, Ashley B.; Cooper, Bruce; Kark, Adrian; Roger, Simon D. // Nephrology Dialysis Transplantation;Mar2010, Vol. 25 Issue 3, p920 

    Background. An optimal haemoglobin (Hb) response to erythropoietin requires elevated iron indices in dialysis patients; however, it is unknown if the same applies in chronic kidney disease (CKD).

  • Pharmacy abstracts presented at CANNT 2005 in Halifax, Nova Scotia.  // CANNT Journal;Oct-Dec2005, Vol. 15 Issue 4, p11 

    This section presents abstracts of articles on pharmacy presented at the Canadian Association of Nephrology Nurses and Technologists 2005 symposium in Halifax, Nova Scotia. The abstracts include "Individualized Heparin Aliquots As a Cost Savings Initiative in the Hemodialysis Unit," by Jenny Ng...

  • Influence of erythropoietin-stimulating agent treatment on glycated hemoglobin values in diabetic patients with chronic kidney disease. Okada, Tomonari; Nakao, Toshiyuki; Matsumoto, Hiroshi; Nagaoka, Yume; Wada, Toshikazu // Clinical & Experimental Nephrology;Apr2011, Vol. 15 Issue 2, p316 

    No abstract available.

  • Blood Pressure Increase After Erythropoietin Injection in Hemodialysis and Predialysis Patients. Noshad, Hamid // Iranian Journal of Kidney Diseases;May2013, Vol. 7 Issue 3, p220 

    Introduction. Anemia is among the most important complications of chronic kidney disease (CKD) and a lot of symptoms and signs are due to this problem. Erythropoietin injection may improve anemia, but it may cause hypertension in these patients. The aim of this study is to evaluate...

  • Vascular changes in hemodialysis patients in response to recombinant human erythropoietin. London, Gérard M.; Zins, Brigitte; Pannier, Bruno; Naret, Catherine; Berthelot, Jean-Michel; Jacquot, Christian; Safar, Michel; Drueke, Tilman B. // Kidney International;Nov1989, Vol. 36 Issue 5, p878 

    The partial correction of anemia with recombinant human erythropoietin (rHuEpo) is frequently associated with an increase in arterial pressure and could oppose the beneficial effect of anemia correction on myocardial function. In order to analyze the influence of rHuEpo therapy on the vessels...

  • Bone marrow changes following treatment of renal anemia with erythropoietin. Horina, Jörg H.; Schmid, Christine R.; Roob, Johannes M.; Winkler, Hanns M.; Samitz, Michael A.; Hammer, Heinz F.; Pogglitsch, Helmut; Krejs, Guenter J. // Kidney International;Nov1991, Vol. 40 Issue 5, p917 

    In 14 severely anemic patients with end-stage renal disease and chronic hemodialysis the effect of recombinant human erythropoietin (EPO) on hemopoiesis was investigated. Bone marrow biopsies were taken before and after four and 26 months of treatment with EPO to evaluate quantitative and...

  • Modeling red blood cell survival data. Korell, Julia; Vos, Frederiek; Coulter, Carolyn; Schollum, John; Walker, Robert; Duffull, Stephen // Journal of Pharmacokinetics & Pharmacodynamics;Dec2011, Vol. 38 Issue 6, p787 

    Anaemia of chronic kidney disease (CKD) is a common complication in patients with renal impairment, especially in end-stage renal failure. As well as erythropoietin deficiency, decreased red blood cell survival is a contributing factor. However, it remains unclear which mechanism underlies the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics